Optimal DAPT duration
interview with clinical expert Dr. Muramatsu
interview with clinical expert Dr. Muramatsu
Are you interested in short DAPT? Learn more…
What
The MASTER DAPT trial is and how is applies to short DAPT.
Why
The MASTER DAPT trial is different to other clinical studies on short DAPT?
How
A short DAPT protocol fits with established guidelines?
Dr. Muramatsu is here to help you find some answers
Summary download for optimal DAPT protocol
The interview is in five parts and takes a total of 25 minutes to watch.
A summary of the interview can be simple to confirm.
Behind the MASTER DAPT Trial
Learn how the MASTER DAPT trial differs to other short DAPT studies, as Dr. Muramatsu introduces the trial’s background and its main considerations.
Get insight
Short DAPT Guidelines across the Globe
Update your knowledge on recent short DAPT guidelines as Dr. Muramatsu looks at guidelines in US, Europe and Japan.
Get insight
How do you decide the duration for short DAPT?
Learn how to decide a short DAPT duration, as Dr. Muramatsu shares the short DAPT protocol at his hospital before and after the MASTER DAPT trial.
Get insight
What is the future of short DAPT?
Find out which tools can help improve patient wellbeing in short DAPT, as Dr. Muramatsu shares his opinion on the importance of drug eluting stents in a short DAPT procedure.
Read more about the MASTER DAPT Trial
Sub-analysis: Complex PCI
Read the latest results from the MASTER DAPT Complex PCI sub-analysis.
Sub-analysis: OAC
Read the summary report for the MASTER DAPT OAC sub-analysis result.
Summary of main trial
Read the summary report of the MASTER DAPT main trial result.
Our Ultimaster™ stent, used in the MASTER DAPT trial, has three innovative features which help support a short DAPT strategy.
1. Stent Flexibility
Flexible 80μm Cocr platform with optimal conformability to reduce mechanical stress on the vessel wall.
2. Gradient Coating Technology
Elastic gradient PDLLA-PCL short term polymer exposure mirrors biological response, promoting rapid vascular repair within 3-4 months.
3. Abluminal Coating Technology & Drug
Silorimus: Most proven drug on stents. Drug release matches biological response targeted abluminal drug delivery. Low Nominal drug dose: 3.9μg/mm or 0.7μg/mm2
Ultimaster™
Terumo’s proprietary bioresorbable polymer coating and two-link design help facilitate smoother access. Discover how the UltimasterTM stent can ensure optimal deliverability and potentially shortened DAPT time.
New MASTER DAPT Webinars to Optimize your DAPT StrategyNew MASTER DAPT Webinars to Optimize your DAPT Strategy
The results of the MASTER DAPT study proved the non-inferiority of short DAPT, and helped bridge the current knowledge gap on DAPT duration in high bleeding risk patients. Understand the potential impact on DAPT guidelines and how to select the optimal DAPT duration for your patients with our collection of MASTER DAPT webinars from around the globe.
